



Item 7.01. Regulation FD Disclosure.

On Wednesday, January 10th at 2:30 pm PT at the 36th Annual J.P. Morgan Healthcare Conference (the "Conference"), PTC Therapeutics, Inc. (the "Company") will highlight the Company's 20-year commitment to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders, the company's 2018 strategic priorities, preliminary 2017 financial results and 2018 financial guidance. The presentation will be webcast live and the accompanying slide deck has been posted on the Events and Presentations page under the Investors section of the Company's website. A copy of the slide deck, which the Company intends to utilize in various meetings at the Conference, is also attached as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	<u>Corporate Presentation - 36th Annual J.P. Morgan Healthcare Conference</u>

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: January 10, 2018 By: /s/ Christine Utter  
Name: Christine Utter  
Title: Principal Financial Officer